Physician factors as an indicator of technological device adoption

Journal of Medical Systems

Volumn 30, Issue 3, 2006, Pages 177-186

  Artis, Latoya C ^a   Burkhart, Theresa M ^b   Johnson, Tricia J ^b   Matuszewski, Karl A ^c  

^a RUSH UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c University HealthSystem Consortium ^*  (United States)

Author keywords

Adoption curve; Interventional cardiologists; Medical devices; Outcomes; Technology adoption

Indexed keywords

ADULT; AGED; ARTICLE; AWARENESS; CARDIOLOGIST; COMMUNITY HOSPITAL; DATA BASE; DRUG ELUTING STENT; FACTORIAL ANALYSIS; FORECASTING; HUMAN; JOB ADAPTATION; MALE; MEDICAL TECHNOLOGY; METAL STENT; PHYSICIAN; QUESTIONNAIRE; STENT; TECHNOLOGY; UNIVERSITY HOSPITAL;

CARDIOLOGY; DATABASES, FACTUAL; DIFFUSION OF INNOVATION; DRUG UTILIZATION REVIEW; ILLINOIS; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; STENTS; TECHNOLOGY, MEDICAL;

EID: 33745932290     PISSN: 01485598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10916-005-8066-2     Document Type: Article

References (23)

1. Oleske, D., Epidemiology and the Delivery of Health Care Services: Methods and Applications, Plenum, New York, p. 401.
2. Huckman, R. S., and Pisano, G., Turf battles in coronary revascularization. N. Engl. J. Med. 9:857-859, 2005.
3. Bhatia, V., Bhatia, R., and Dhindsa, M., Drug-eluting stents: New era and new concerns. Postgrad. Med. J. 80:13-19, 2004.
4. Finarelli, Jr., and Hugo, J., Could your financial health be heading lor heart break? Costly drug-elutmg stents could dramatically alter projected demands for cardiac surgical services. Healthc. Financ. Manage. 57:68-73, 2003.
5. Kuntz, R., and Baim, D., Defining coronary restenosis: Newer clinical and angiographic paradigms. Circulation 88:1310-1323, 1993.
6. Cummings, J., Technology Report: Drug Eluting Stents, University HealthSystem Consortium, 2002.
7. Dobesh, P. P., Stacy, Z. A., Ansara, A. J., and Enders, J. M., Drug-eluting stents: A mechanical and pharmacological approach to coronary artery disease. Pharmacotherapy 24:1554-1577, 2004.
8. van der Hoeven, B., Pires, N., Warda, H., Oemrawsingh, P., and Jukema, J., Drug Eluting Stents: Results, Promises, and Problems, Elsevier Ireland, 2004.
9. Colombo, A., and Iakovou, I., Drug eluting stents: The new gold standard for percutaneous coronary revascularization. Eur. Heart J. 25(6):895, 2004.
10. Stanik-Hutt, J., Drug-coated stents: Preventing restenosis in coronary artery disease. J. Cardiovasc. Nurs. 19:404-408, 2004.
11. Hout, B., Serruys, P., and Lemos, P., One-year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: An analysis from the RAVEL trial. Heart 91:507-512, 2005.
12. Weintraub, W. S., Economics of sirolimus-eluting stents: Drug eluting stents have really arrived. Am. Heart Assoc. 110:472-474, 2004.
13. Conti, C. R., Drug eluting stents versus bare metal stents. Clin. Cardiol. 26:493-494, 2003.
14. Anonymous, Drug eluting stents: Researchers measure healthcare costs of restenosis. Cardiovasc. Watch 4-5, 2004.
15. Baim, D., New devices for percutaneous coronary intervention are rapidly making bypass surgery obsolete. Curr. Opin. Cardiol. 19:593-597, 2004.
16. Anonymous, Coronary Revascularization: Impact of Drug-Eluting Stents (DES) SG2, 2004.
17. Moore, G., Crossing the Chasm, HarperCollins, New York, p. 256.
18. Stephenson, G., The somewhat flawed theoretical foundation of the extension service. J. Extension 41, 2003.
19. Stavins, J., Effect of consumer characteristics on the use of payment instruments. N. Engl. Econ. Rev. 19-32, 2001.
20. Glass, H. E., and Rosenthal, B., Demographics, practices, and prescribing characteristics of physicians who are early adopters of new drugs. PT 29:699-708, 2004.
21. Escarce, J., Externalities in hospitals and physician adoption of a new surgical technology: An exploratory analysis. J. Health Econ. 15:715-734, 1996.
22. Edlefsen, K. L., Mandelson, M. T., McIntosh M. W., Andersen, R., Wagner, E. H., and Urban, N., Prostate-specific antigen for prostate cancer screening: Do physician characteristics affect its use? Am. J. Prev. Med. 17:87-90, 1999.
23. Gunn, J., Morton, A. C., Wales, C., Newman, C. M. H., Crossman, D. C., and Cumberland, D. C., Drug eluting stents: Maximizing benefit and minimizing cost. Heart 89:127-138.